2020
DOI: 10.2147/ijn.s215137
|View full text |Cite
|
Sign up to set email alerts
|

<p>Combined Therapeutic Effects of <sup>131</sup>I-Labeled and 5Fu-Loaded Multifunctional Nanoparticles in Colorectal Cancer</p>

Abstract: Background: Owing to its combined effects, the co-delivery of different therapeutics is a promising option for the treatment of cancer. In the present study, tumor-targeting poly (ethylene glycol)-poly(lactic acid) (PEG-PLA) nanoparticles were developed for the transportation of two molecules, namely chemotherapeutic drug 5-fluorouracil (5Fu) and radionuclide iodine-131 (131 I), in a single platform. Methods: The obtained nanoparticles (Cetuximab [Cet]-PEG-PLA-5Fu-131 I) were spherical (diameter approximately … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
21
0

Year Published

2021
2021
2025
2025

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 19 publications
(22 citation statements)
references
References 35 publications
1
21
0
Order By: Relevance
“…In the past, sdAbs against a variety of membrane-bound cancer biomarkers such as CEA (49), EGFR (52), HER2 (49), PSMA (53), and CD20 (54,55) have been successfully evaluated as in vivo theranostic tracers, using a variety of radionuclides in (non-)clinical studies. The most advanced sdAb under clinical evaluation is a sdAb targeting HER2 that after labelling with 68 Ga, identified both primary HER2 + tumors and related metastasis as early as one hour post injection in a phase I study (56). Recently, the biodistribution of the same sdAb labelled with 131 I in six healthy volunteers and three patients with metastatic breast cancer was reported (57).…”
Section: Single Domain Antibodiesmentioning
confidence: 99%
See 1 more Smart Citation
“…In the past, sdAbs against a variety of membrane-bound cancer biomarkers such as CEA (49), EGFR (52), HER2 (49), PSMA (53), and CD20 (54,55) have been successfully evaluated as in vivo theranostic tracers, using a variety of radionuclides in (non-)clinical studies. The most advanced sdAb under clinical evaluation is a sdAb targeting HER2 that after labelling with 68 Ga, identified both primary HER2 + tumors and related metastasis as early as one hour post injection in a phase I study (56). Recently, the biodistribution of the same sdAb labelled with 131 I in six healthy volunteers and three patients with metastatic breast cancer was reported (57).…”
Section: Single Domain Antibodiesmentioning
confidence: 99%
“…Krasniqi et al generated sdAbs targeting CD20 and used them as radiolabeled agents for imaging and TRNT of CD20 + lymphomas (54). In a preclinical model of CD20 + lymphoma, micro-PET/CT images generated in mice that received a 68 Galabelled CD20-targeting sdAb revealed specific tumor targeting as early as one hour post injection. The background signal was low in all non-target organs, except the kidneys and bladder through which the unbound fraction is cleared rapidly.…”
Section: Non-hodgkin Lymphomamentioning
confidence: 99%
“…However, the radio-chemotherapy combination Cet–PEG–PLA–5FU- 131 I (5 FU 0.625 µg/mL and 1.85 MBq/mL of 131 I) resulted in significantly higher cytotoxicity when compared to monotherapy. Consequently, the Cet–PEG–PLA–5FU- 131 I nanoparticle system showed prolonged blood circulation and effective tumor accumulation [ 62 ].…”
Section: Polymeric Nanoparticlesmentioning
confidence: 99%
“…In this regard, the efficacy of these chemotherapeutic drugs is not ideal due to significant toxicity and side effects, as well as the putative induction of multi-drug resistance. Although complementary modalities such electroporation and nanoparticles have dramatically improved the therapeutic efficacy of chemotherapeutic agents in CRC, the main limitation of chemotherapy technique is severe cytotoxicity [85][86][87][88][89]. Actually, about 50% of patients with metastatic CRC show a progressive disease within 7-9 months after drug treatment, with a median survival of 20 months and a 5-year survival rate of less than 5%.…”
Section: Anti-cancer Effects Colorectal Cancermentioning
confidence: 99%